隶属于 qiagen nv
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Qiagen received FDA clearance for its QIAstat-Dx Bloodstream Panel, expanding its syndromic testing portfolio for bloodstream infection diagnosis. - The new launch is positioned by analysts as a signal of a potential turnaround for Qiagen's business and syndromic testing franchise. - The clearance addresses clinical demand for rapid, multiplexed identification of pathogens implicated in bloodstream infections. - The development carries significance for healthcare professionals seeking faster diagnostic results to guide antimicrobial and clinical decision-making.
- The global single-cell multiomics market, valued at USD 2.99 billion in 2025, is projected to reach USD 18.20 billion by 2035 at a CAGR of 19.81%, according to SNS Insider. - Oncology dominated the application segment with a 38.90% revenue share in 2025, while single-cell proteomics is expected to grow at the fastest CAGR of 23.16% through 2035. - Droplet-based microfluidics accounted for 56.30% of market revenue in 2025, though spatial-omics platforms are forecast to achieve the highest CAGR of 24.50%. - North America led regional markets with 41.85% of total revenue, while Asia Pacific is anticipated to register the strongest growth over the forecast period.
- The North America DNA sequencing market was valued at USD 7.5 billion in 2025 and is projected to reach USD 27.56 billion by 2035, growing at a CAGR of 13.9%. - Next-generation sequencing dominates the technology segment with a 63.80% share in 2025, while consumables lead product categories at 54.70%. - Oncology represents the largest application segment at 29.40%, reflecting high cancer prevalence and the shift toward targeted tumor profiling and companion diagnostics. - Illumina holds the largest market share with its sequencing-by-synthesis systems, followed by Thermo Fisher Scientific and Pacific Biosciences as key competitors.
- Parse Biosciences and bit.bio announced a landmark alliance to create a comprehensive map of transcription factor-driven cell identity that will serve as a foundational blueprint for developing human-relevant models at scale. - The collaboration will leverage massively parallel causal transcriptomics to test thousands of genetic variables simultaneously, combining bit.bio's opti-ox cell programming technology with Parse's Evercode single cell sequencing platform. - The resulting dataset will establish clear causal links between genetic changes and biological outcomes, enabling AI models to predict cellular responses to drugs and diseases while advancing predictive medicine capabilities. - This foundational map aims to guide the wider industry on therapy design and human cell manufacturing at scale, moving the field closer to reliably replicating human biology.
- Moleculent AB closed a $20 million financing round led by Rubicon Healthcare Partners to scale its functional profiling platform that maps cell-cell communication in human tissue. - The technology uses proprietary Proximity Ligation Assay to detect cell interactions in their native environment, addressing a critical gap in understanding how cells communicate within tissues. - Strong demand from research institutions and pharmaceutical partners across Europe and the US has prompted expansion of the company's Techstart Early Access Program. - The funding will accelerate commercial operations in the United States and drive the commercial launch of an automated instrument for large-scale studies.
- QIAGEN announced the acquisition of Parse Biosciences for $225 million upfront plus potential milestone payments, expanding its portfolio into the rapidly growing single-cell sequencing market. - Parse's Evercode platform enables instrument-free analysis of millions to billions of cells, addressing the increasing demand for large-scale datasets in AI-driven drug discovery. - The acquisition positions QIAGEN to capitalize on the single-cell market expected to grow from $1.2 billion in 2024 to $2.1 billion by 2029, driven by pharmaceutical companies' need for massive cellular datasets.
- Hologic received FDA 510(k) clearance and European CE marking for its Panther Fusion Gastrointestinal Bacterial and Expanded Bacterial Assays, marking the company's entry into GI pathogen diagnostics. - The molecular tests rapidly detect common bacterial pathogens causing infectious gastroenteritis, including Salmonella, Campylobacter, Shigella, E. coli, Vibrio, Yersinia and Plesiomonas, addressing a significant healthcare burden with nearly 200 million annual US cases. - The customizable mini-panel format allows laboratories to run tests individually or in combination, reducing labor-intensive traditional culture methods while supporting faster diagnosis and antimicrobial stewardship. - The assays integrate with Hologic's established Panther Fusion System platform, expanding the company's molecular diagnostics menu beyond women's health and sexually transmitted infections into infectious gastroenteritis testing.
- Tempus AI received FDA 510(k) clearance for its Tempus xR IVD device, an RNA-based next-generation sequencing diagnostic tool for cancer research. - The device detects gene rearrangements in solid tumor tissue specimens and will support drug development programs for biopharma partners. - RNA sequencing offers deeper insights into disease mechanisms beyond DNA analysis, enabling more precise patient selection for therapies and efficient clinical trial design. - The FDA authorization strengthens Tempus's position as a comprehensive precision medicine solutions provider with its growing multimodal dataset and AI-enabled diagnostics.
- Qiagen launched its FDA-cleared QIAstat-Dx Rise syndromic testing system globally across more than 100 countries in early October 2025. - The automated molecular diagnostics platform is designed to boost diagnostic speed and reduce hands-on time for hospitals and laboratories. - This marks Qiagen's third FDA-cleared syndromic testing product in 2025, demonstrating aggressive portfolio expansion. - The company raised its full-year 2025 financial guidance following the launch, reflecting confidence in market demand and operational momentum.
- QIAGEN launched QIAstat-Dx Rise, a high-throughput version of its automated syndromic testing system that received FDA clearance and can process up to 160 samples per day. - The system offers automated loading and unloading of cartridges with minimal hands-on time, designed for hospitals and reference laboratories requiring rapid infectious disease diagnostics. - This marks QIAGEN's third FDA-cleared QIAstat-Dx product in 2025, building on a portfolio of six panels cleared over the last 12 months. - The system is already available in over 100 countries with more than 4,600 instruments placed globally through the first half of 2025.
